TYRA

Tyra Biosciences, Inc. (TYRA) | Rumor.io

Tyra Biosciences

TYRA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,722

Bullish sentiment (50-day avg)73%

Price to earnings ratio-10.7

Market capitalization1.5B

Earnings per share-2.39

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-119.9M

Social

What share of all stock conversation is about TYRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 9

Tyra Biosciences, Inc. ($TYRA) reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, with a 79% overall response rate and 64% complete response at three months.
The market reacted negatively to the results, with the stock price plunging 34.3% premarket, and the company's market capitalization dropping to $1.6B.
The primary catalyst for the sell-off was the company's failure to meet the expected 70-80% headline complete response threshold, despite reporting a clean safety profile and a 57% complete response rate at three months.

Generated by AI

Sentiment

Of the messages about TYRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	72.73%	94.69% -5.31
Bearish	—	—	27.27%	5.31% new

Topics

Of the messages about TYRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	37.85%	52.92%
Analysts	—	0%	28.13%	23.95%
Technical Analysis	—	0%	6.65%	10.63%
Macro	—	0%	27.37%	12.5%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%

Community

Of the messages about TYRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	50%	42.77%	21.94%
Newcomers	100%	50%	57.23%	78.06%

Sep 9

The company's Phase 2 SURF302 study results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer showed a 79% overall response rate and 57% complete response at three months, but fell short of the market's expected 70% complete response rate threshold.
The market's negative reaction to the results is driven by the perceived underwhelming efficacy of the treatment, with many investors expecting a higher complete response rate.
Despite the mixed results, the company's safety profile remains favorable, and the data support its planned Phase 3 strategy, offering a path forward for the treatment's development.

Generated by AI

Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor. The study enrolled patients with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At the August 31, 2026 cutoff, 14 participants receiving 60 mg once daily had received treatment and completed at least the three-month disease assessment, […]

13d agoYahoo Finance

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value. With the stock resetting after mixed bladder cancer drug data and a sizeable equity offering, the question is how closely that current market price lines up with the assets on its balance sheet. Over the past year, Tyra Biosciences has gained about 105.7%, which raises the issue of whether that move...

13d agosg.finance.yahoo.com

Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday

15d agoBenzinga

Why is Tyra Biosciences stock surging today?

15d agoInvesting.com

Also Discussed

Investors talking about TYRA also mention

#	Name	Attention
1	Capricor Therapeutics, Inc.CAPR	0.35%+0.26
2	Tango Therapeutics Inc.TNGX	0%new
3	Nektar TherapeuticsNKTR	0.08%+0.03
4	Sarepta Therapeutics, Inc.SRPT	0%-0.01
5	Dianthus Therapeutics Inc.DNTH	0%0
6	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
7	Relmada Therapeutics Inc.RLMD	0%0
8	Frequency Electronics, Inc.FEIM	0%0
9	Ovid Therapeutics Inc.OVID	0%0
10	BioAge Labs, Inc.BIOA	0.01%+0

Tyra Biosciences, Inc.

Healthcare
Biotechnology

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization. Tyra Biosciences is advancing oral dabogratinib across urologic cancers and skeletal dysplasia programs, alongside other FGFR-targeted candidates in its pipeline. Its current business is built around clinical development, translational research, and precision oncology, with an emphasis on conditions where specific genetic alterations drive disease. Headquartered in Carlsbad, California, Tyra Biosciences operates as a focused biotechnology developer serving the oncology and rare disease markets.

Website

Location

2656 State Street

Carlsbad, CA, 92008

United States

Social

What share of all stock conversation is about TYRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 9

Tyra Biosciences, Inc. ($TYRA) reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, with a 79% overall response rate and 64% complete response at three months.
The market reacted negatively to the results, with the stock price plunging 34.3% premarket, and the company's market capitalization dropping to $1.6B.
The primary catalyst for the sell-off was the company's failure to meet the expected 70-80% headline complete response threshold, despite reporting a clean safety profile and a 57% complete response rate at three months.

Generated by AI

Sentiment

Of the messages about TYRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	72.73%	94.69% -5.31
Bearish	—	—	27.27%	5.31% new

Topics

Of the messages about TYRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	37.85%	52.92%
Analysts	—	0%	28.13%	23.95%
Technical Analysis	—	0%	6.65%	10.63%
Macro	—	0%	27.37%	12.5%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%

Community

Of the messages about TYRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	50%	42.77%	21.94%
Newcomers	100%	50%	57.23%	78.06%

Sep 9

The company's Phase 2 SURF302 study results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer showed a 79% overall response rate and 57% complete response at three months, but fell short of the market's expected 70% complete response rate threshold.
The market's negative reaction to the results is driven by the perceived underwhelming efficacy of the treatment, with many investors expecting a higher complete response rate.
Despite the mixed results, the company's safety profile remains favorable, and the data support its planned Phase 3 strategy, offering a path forward for the treatment's development.

Generated by AI

Tyra Biosciences

Social

Sep 9

Sentiment

Topics

Community

Sep 9

News

Bladder Cancer Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday

Why is Tyra Biosciences stock surging today?

Also Discussed

Tyra Biosciences, Inc.

Company Information

Location

News

Bladder Cancer Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday

Why is Tyra Biosciences stock surging today?

Also Discussed

Social

Sep 9

Sentiment

Topics

Community

Sep 9